Sinusoidal obstruction syndrome following myeloablative therapy and tranexamic acid treatment for hemorrhage in two patients with neuroblastoma

Tools

Preview

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
449kB

Item Type:	Article
Title:	Sinusoidal obstruction syndrome following myeloablative therapy and tranexamic acid treatment for hemorrhage in two patients with neuroblastoma
Creators Name:	Zirngibl, F., Flemmig, C., Lang, P., Künkele, A., Eggert, A., Schulte, J.H. and Deubzer, H.E.
Abstract:	Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic acid (TA), used to prevent/treat excessive blood loss, are rare. We present the clinical course of two young patients (22 and 56 months) receiving busulfan/melphalan (Bu/Mel) high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HSCT) to treat high-risk neuroblastoma, who developed hepatic sinusoidal obstruction syndrome (SOS) within 48 h after systemic TA treatment for a hemodynamically relevant hemorrhage. Defibrotide treatment resolved hepatic SOS, but the short time between TA administration and SOS onset suggests a causal association.
Keywords:	Pediatric Hematopoietic Stem Cell Transplantation, Embryonal Tumor, Transplant-Related Complication, Fibrinolysis Inhibitor, Thrombotic Event
Source:	Children
ISSN:	2227-9067
Publisher:	MDPI
Volume:	7
Number:	11
Page Range:	198
Date:	November 2020
Official Publication:	https://doi.org/10.3390/children7110198
PubMed:	View item in PubMed

Repository Staff Only: item control page

Download Statistics

Downloads

Downloads per month over past year